Sorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With R/R … – StreetInsider.com
EconoTimes |
Sorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR–T Phase 1 Clinical Trial in Patients With R/R …
StreetInsider.com Sorrento Therapeutics, Inc. (NASDAQ: SRNE) and Celularity Inc announced today that the companies have started screening patients for its leading CD38 chimeric antigen receptor (CAR) T cell therapy drug development program, following FDA review allowing … Sorrento Therapeutics (SRNE) and Celularity Enter Clinical Stage Development with CD38 |
